Medication Costs and Health Care Use in Child Asthma

Published Online: Wednesday, April 18, 2012
Follow Pharmacy_Times:
In this video, Dana Goldman, PhD, Director of the Schaeffer Center for Health Policy and Economics at the University of Southern California, discusses the results of a Journal of the American Medical Association study analyzing the effects of cost increases in children’s asthma medication. Using insurance claims, the study authors identified 8800 children being treated with long-term asthma medication and then analyzed data about them to establish how often patients filled prescriptions for daily medications and estimated actual medication use. The study authors then compared use of other medical services, including hospital stays and emergency room visits, to determine whether those services were also affected.

Related Articles
The approximate 1 in 10 asthma patients who have severe disease do not respond to mainstay corticosteroid treatment, even in high doses.
Asthma’s increasingly deleterious morbidity and socioeconomic burden are of tremendous concern to clinicians and public health officials.
The FDA is currently reviewing Teva’s reslizumab treatment for adult and adolescent asthmatics with symptoms inadequately controlled by inhaled corticosteroid (ICS) regimens.
An FDA advisory committee has unanimously recommended approval for GlaxoSmithKline’s mepolizumab severe asthma treatment in adults, but not adolescents.
Latest Issues
$auto_registration$